Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2024.2373324 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients.
Ann Hematol
August 2025
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, China.
High-dose cytarabine has been the frontline therapy for the consolidation treatment of acute myeloid leukemia for many years. Current guidelines suggest that the combination of anthracyclines with high-dose cytarabine can be considered an option for consolidation therapy in certain patients. However, the research in this area is limited.
View Article and Find Full Text PDF[Interventional management of gastrointestinal and uterine bleeding in a patient with acute myeloid leukemia on induction therapy: case report].
Rev Gastroenterol Peru
August 2025
Servicio de Radiología intervencionista, Hospital Universitario Nacional de Colombia, Bogotá, Colombia.
Bleeding involves morbidity and mortality in patients with acute myeloid leukemia (AML) receiving induction therapy. The concomitant presentation of gastrointestinal and uterine bleeding is rare as described in the literature, and its approach is not standardized. The following is an illustration of a case in which interventionism was effective and safe.
View Article and Find Full Text PDFA Case of Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.
Intern Med
July 2025
Department of Hematology, Hamanomachi Hospital, Japan.
FMS-like tyrosine kinase 3 (FLT3) mutations are observed in 30% of acute myeloid leukemia (AML) cases and indicate a poor prognosis. FLT3 inhibitors, such as gilteritinib, improve outcomes but may cause differentiation syndrome (DS) in approximately 3% of patients. We herein report a case of FLT3-tyrosine kinase domain-mutated AML treated with idarubicin and cytarabine, followed by a single dose of gilteritinib.
View Article and Find Full Text PDF[A case of acute promyelocytic leukemia with NUP98::RARG::LINE-L2a tripartite fusion and the mechanism of resistance to all-trans retinoic acid].
Zhonghua Yi Xue Za Zhi
July 2025
Department of Clinical Laboratory, Shandong Provicial Hospital Affiliated to Shandong First Medical University, Jinan 250000, China.
This study reports a novel case of acute promyelocytic leukemia (APL) characterized by a tripartite fusion gene, NUP98::RARG::LINE-L2a, formed by the rearrangement of nucleoporin 98 (NUP98), retinoic acid receptor gamma (RARG), and long interspersed nuclear element L2a (LINE-L2a). The molecular mechanism underlying the patient's resistance to all-trans retinoic acid (ATRA) is also investigated. The 32-year-old male was admitted to Shandong Provincial Hospital Affiliated to Shandong First Medical University with complaints of "a 10-day cough and newly detected leukocytosis for one day".
View Article and Find Full Text PDFAcute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency.
Leuk Res Rep
May 2025
Clinical hematology department of Fattouma Bourguiba Hospital, Monatir, Tunisia.
Background: Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.
View Article and Find Full Text PDF